Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Open Access
- 29 November 2019
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 19 (1) , 1-9
Abstract
Background: There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown repeatedly in this population, but there is still a paucity of data on the efficacy and safety of (a) different routes of administration, and (b) ketamine’s enantiomers esketamine and arketamine. Given practical advantages of oral over IV administration and pharmacodynamic arguments for better antidepressant efficacy of esketamine over arketamine, we designed a study to investigate repeated administration of oral esketamine in patients with TRD. Methods: This study features a triple-blind randomized placebo-controlled trial (RCT) comparing daily oral esketamine versus placebo as add-on to regular antidepressant medications for a period of 6 weeks, succeeded by a follow-up of 4 weeks. The methods support examination of the efficacy, safety, tolerability, mechanisms of action, and economic impact of oral esketamine in patients with TRD. Discussion: This is the first RCT investigating repeated oral esketamine administration in patients with TRD. If shown to be effective and tolerated, oral esketamine administration poses important advantages over IV administration. Trial registration: Dutch Trial Register, NTR6161. Registered 21 October 2016.Keywords
Funding Information
- ZonMw (80-83600-98-3074)
This publication has 81 references indexed in Scilit:
- Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010PLOS Medicine, 2013
- Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P)BMC Health Services Research, 2013
- Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled StudyNeuropsychopharmacology, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Reconsidering anhedonia in depression: Lessons from translational neuroscienceNeuroscience & Biobehavioral Reviews, 2011
- Development and Initial Validation of the Iowa Sleep Disturbances InventoryAssessment, 2010
- Treatment-Resistant Depression and Mortality After Acute Coronary SyndromeAmerican Journal of Psychiatry, 2009
- Comparison of psychic emergence reactions after (±)-ketamine and (+)-ketamine in miceLife Sciences, 2006
- Grading the severity of chronic painPain, 1992
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991